Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain
Introduction: In recent years, target therapies to specific molecular alterations in advanced non–small cell lung cancer (NSCLC) have been identified and have shown superior efficacy compared to non-targeted treatments. Anaplastic lymphoma kinase (ALK) is one of the therapeutic targets; nevertheles...
Main Authors: | Margarita Majem, Rosa Álvarez, Ana Laura Ortega, Lucía Ruiz de Alda, Rocío Gordo, J Francisco García, Yoana Ivanova-Markova, Almudena González-Domínguez, Raquel Sánchez San Cristóbal, Federico Rojo |
---|---|
Format: | Article |
Language: | English |
Published: |
AboutScience Srl
2022-09-01
|
Series: | Global & Regional Health Technology Assessment |
Subjects: | |
Online Access: | https://journals.aboutscience.eu/index.php/grhta/article/view/2449 |
Similar Items
-
Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer
by: Wenjie Liu, et al.
Published: (2024-02-01) -
The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer
by: Yen-Ting Lin, et al.
Published: (2019-09-01) -
Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics
by: Ilija Nenadić, et al.
Published: (2017-07-01) -
Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain
by: Presa M, et al.
Published: (2023-09-01) -
New Advances in Liquid Biopsy Technologies for Anaplastic Lymphoma Kinase (ALK)—Positive Cancer
by: Matteo Villa, et al.
Published: (2021-10-01)